FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review

The Johnson and Johnson vaccine has been reapproved for use as it's been weighed that the vaccine's benefits far outweigh the risks. The blood clots that have occurred are extremely rare and have all occurred in women between the ages of 18 and 59, 6 to 15 days after their vaccination. After extensive review, the FDA and CDC have acknowledged that they will continue to monitor the situation but that the vaccine protects people from illness, hospitalization, and death, and that patients should know the possible side effects. With the Johnson and Johnson vaccine being so much more easily distributable, it's likely that some of your patients will be offered this vaccine in the coming weeks. This information will be useful in addressing their concerns and ensuring them that the risk is well worth the benefit.